Santander

• A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi … Ended
  2022-501601-12-00 4 2023-05-22 Diffuse large B-cell Lymphoma
• STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BEMNIFOSBUVIR AND RUZASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION Ended
  2023-504566-28-00 4 2023-05-19 Chronic Hepatitis C Virus (HCV) Infection
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 5 2023-05-05 Pulmonary Arterial Hypertension (PAH)
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous efzofitimod in patients wit … Ended
  2023-506039-13-00 5 2023-04-12 pulmonary sarcoidosis
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel … Ended
  2023-509243-27-00 4 2023-04-12 Moderate-to-Severe Uncontrolled Asthma
• A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended
  2022-501425-20-00 4 2023-04-03 Rheumatoid Arthritis Arthritis Joint Diseases Musculoskeletal Disea
• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 4 2023-03-30 Non-alcoholic Fatty Liver Disease
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o … Ended
  2023-508860-31-00 5 2023-02-28 Stage IV colon or rectal adenocarcinoma (mCRC).
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended
  2024-514761-19-00 5 2023-01-25 Idiopathic Pulmonary Fibrosis
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 5 2023-01-09 Hepatitis B, Chronic
• A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi … Ended
  2022-500594-13-00 4 2022-12-14 "Non-Alcoholic Steatohepatatis (NASH) is the progressive form of Non-A
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended
  2024-511281-36-00 5 2022-11-17 Refractory Invasive Pulmonary Aspergillosis
• Study to evaluate the impact of VCN-01 on the overall survival of patients with advanced pancreatic cancer treated with standard therapy. Ended
  2024-511290-30-00 4 2022-11-15 Metastatic Pancreatic Cancer
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• Zibotentan and Dapagliflozin combination, Evaluated in Liver cirrhosis (ZEAL study) Ended
  2023-505405-17-00 4 2022-10-07 Liver cirrhosis with features of portal hypertension.
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended
  2023-503615-14-00 4 2022-09-29 Relapsed or Refractory Classical Hodgkin Lymphoma
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease

Showing 505–528 of 596 trials